3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase NA
1
Phase 4
1
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
4
Adenocarcinoma of Lung
2
Recurrence
1
Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder)
1
Neoplasms
1
Liver Neoplasms
1
Glioblastoma
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Solid Tumor
1
Interventions
Radiotherapy
10
fludarabine phosphate
9
Peripheral Blood Stem Cell Transplantation
8
Cyclosporine
7
Cyclophosphamide
7
Busulfan
7
Whole-Body Irradiation
6
Melphalan
6
Radiofrequency Ablation
5
Mycophenolic Acid
5
Filgrastim
5
Antilymphocyte Serum
5
Surveys and Questionnaires
4
Surgical Procedures, Operative
4
Methotrexate
4
Etoposide
4
Drug Therapy
4
Cisplatin
4
fludarabine
3
Radiosurgery
3
Injections
3
Hepatectomy
3
Cord Blood Stem Cell Transplantation
3
thymoglobulin
2
lenvatinib
2
Vinblastine
2
Videotape Recording
2
Thiotepa
2
Standard of Care
2
Sorafenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase NA
×
Recurrence
×
tislelizumab
×
Clear all
NCT05277675
2022-03-14
RANT
Southwest Hospital, China
Phase NA
Unknown
160 enrolled